Navigation Links
ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
Date:9/15/2010

EXTON, Pa., Sept. 15 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections (CDI), a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.  VP20621 contains the spores of a naturally occurring non-toxin producing strain of C. difficile.  

The poster entitled 'Phase 1 Evaluation of an Oral Suspension of VP 20621, Spores of a Non-Toxigenic C. difficile Strain (NTCD), in Healthy Older Subjects Pretreated With Oral Vancomycin' is being presented today at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in poster session F1-2127b by Stephen Villano, M.D., ViroPharma's vice president of clinical research and development.

The Phase 1 study was designed to determine the safety and tolerability of VP20621 dosed orally as single and repeat escalating doses in healthy young (18 to 45 years of age) and older (60 years of age and older) adults.  Because VP20621 was shown to be well tolerated following single and repeat doses in younger and older healthy subjects, the company also performed repeat dosing in older adults following exposure to oral antibiotic.  The new data presented today was from healthy subjects above 60 years of age who were pre-dosed with oral vancomycin to disrupt their gastrointestinal flora and render them potentially susceptible to C. difficile colonization. Subjects were subsequently given either placebo or VP20621 doses of 10(4),10(6), or 10(8) spores (once daily for 14 days).  Conclusions from the study include:

  • Multiple doses of VP20621 were ge
    '/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014  CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today that ... Officer, has been elected to the Company,s Board of ... G. Anderson , Executive Chairman of CryoLife, stated, "Since joining ... an excellent leader who is well positioned to maximize ...
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms of ... or unnoticed, but new technology, coupled with yearly, ... leading to earlier detection of eye diseases, including ... million Americans. If left untreated, these diseases can ... Recently, optometric researchers have deployed ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3
... ADA,s 2009 Convention -- When Shawnae Jebbia won the Miss ... fairytale career. She appeared at events throughout the world, worked ... Shawnae,s world unexpectedly changed when she was diagnosed with hearing ... she had a difficult time understanding and accepting the sudden ...
... Oct. 29 Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... , Sales in local currency declined by 12% in ... negative currency impact. , Net earnings per diluted ... third quarter of 2008. Adjusted EPS was $1.36, a 6% ...
Cached Medicine Technology:Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 4Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 5Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 6Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 7Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 8Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 9Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 10Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 11Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 12Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 13
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... Black women undergoing in vitro fertilization (IVF) are only about ... the popular assisted reproduction technique, new research indicates, and the ... In the study, about 31 percent of white patients became ... patients. Analyzing more than 4,000 IVF cycles over two ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... may lead to increased blood pressure, according to a new ... in blood pressure for young adult women or for teenagers, ... drank lightly or moderately, their risk of high blood pressure ... parallels studies in older adult men and women," said lead ...
(Date:10/22/2014)... -- Measures taken by Firestone officials at the company,s ... limited the spread of the disease there and could ... Rubber Co. provides health services to about 80,000 employees, ... communities. Between Aug. 1 and Sept. 23, there ... 80,000 people. That incidence rate of 0.09 percent was ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... cameraman who was diagnosed with Ebola while working for NBC ... and can leave the special isolation unit at Nebraska Medical Center ... weeks, the hospital said Tuesday. A blood test confirmed by ... Mukpo, 33, can head home to Providence, R.I., NBC News ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... Erica Davis, Subject ... and Heart Disease , ... CA (PRWEB) May 17, 2010 -- One of the race participants in this year’s Strawberry ... That person is Erica Davis., , , , , ,Since a one-in-five-million genetic anomaly left ...
... defence mechanism against heart disease could be switched on by ... University of Leeds. The University of Leeds biologists have ... can limit the production of inflammatory cytokines proteins that ... found that this protective effect can be triggered by pregnenolone ...
... had depression, substance abuse in youth, study finds , ... psychological disorders such as depression and substance abuse appear ... research suggests. , Those who experience mental health difficulties ... maximize their educational opportunities, and they are also likely ...
... ... how to achieve the highest conversion performance. , ... Encino, CA (PRWEB) May 14, 2010 -- T3Leads, a ... marketing industry. Founded in 2006, T3Leads has since provided unparalleled performance and cutting-edge efficiency ...
... ... is once again pleased to announce that a superb physician has joined the Practice — ... ... LLP (ENTA) is once again pleased to announce that a superb physician has joined the ...
... study published last week in Archives of Internal Medicine ... lowered total and LDL-cholesterol levels, in addition to triglycerides. ... counties, is the most comprehensive study of its kind and ... risk of cardiovascular disease. The report, authored by Dr. ...
Cached Medicine News:Health News:First Paraplegic Woman to Climb Mt. Kilimanjaro to Race at Vista's Strawberry Festival 2Health News:'Fountain of youth' steroids could protect against heart disease 2Health News:Kids' Psychological Problems Have Long-Term Effects 2Health News:T3Leads Provides Latest Industry News: Imperative Information to Help Publishers Maximize Profits 2Health News:T3Leads Provides Latest Industry News: Imperative Information to Help Publishers Maximize Profits 3Health News:ENT and Allergy Associates Welcomes Tamekia L. Wakefield, MD, Further Reinforcing its Pediatric Sinus Expertise and Capabilities in Queens , , 2Health News:ENT and Allergy Associates Welcomes Tamekia L. Wakefield, MD, Further Reinforcing its Pediatric Sinus Expertise and Capabilities in Queens , , 3Health News:Pistachios: A handful a day may keep the cardiologist away 2
Symbia T, a TruePoint SPECTCT system, combines a dual-detector variable angle gamma camera with a CT scanner optimized for rapid, accurate attenuation correction of the nuclear data....
... analyzer and data management system ,RADIANCE ... traditional needs of data management systems (DMS), ... management of STAT analyzer systems., ,The RADIANCE ... solution for both STAT analyzers and hospital ...
... is a comprehensive IT solution that ... admission to follow-up. This scalable solution ... diagnostic tools from syngo Dynamics with ... longitudinal clinical repository that becomes a ...
... the AXIOM Artis dBC Magnetic Navigation ... navigation system equipped with digital flat ... is uniquely capable of improving the ... to facilitate increased efficiency and productivity ...
Medicine Products: